1 INTRODUCTION

Acute paraplegia after treatment with intrathecal methotrexate requires spinal cord neuroimaging and electrodiagnosis. We describe two cases of methotrexate neurotoxicity, with absent lumbosacral F wave as early direct motor root toxicity. Due to the poor prognosis observed in eleven cases reviewed, this finding provides a rationale for an early screening.

An early diagnosis of acute motor impairment during chemotherapy may be relevant to prevent paraplegia, especially in patients with hematologic neoplasia. Intrathecal (it) chemotherapeutic regimens such as methotrexate (MTX) combined with cytarabine arabinoside (Ara-C) are used as treatment and prophylaxis of central nervous system (CNS) leukemia.\(^1\)\(^2\) Neurological complications of this chemotherapy vary from asymptomatic chemical arachnoiditis to stroke-mimics, leukoencephalopathy, myelopathy, and/or cauda equina syndrome.\(^3\)\(^7\) MTX is a dihydrofolate reductase inhibitor that induces experimental demyelination.\(^8\) Despite the mechanisms of MXT toxicity are unclear, some authors suggested to be dose dependent and related to a possible reduce clearance\(^9\) in cerebrospinal fluid while others related to a local depletion of folate due to MTX consumption folate\(^10\) and the improvement after folic acid supplementation.\(^11\)\(^12\)

Electrophysiological studies may help in useful in this setting. Among all the findings, the F wave latency measures the conduction time in motor fibers from the stimulus site to the spinal cord and subsequent return to the peripheral site of recording. Its absence provides evidence of conduction block of anterior rami at specific root level and has been considered specific for demyelination.\(^13\)

We reported two cases of acute neurotoxicity related to MTX-it with an early neurophysiological screening that help to define poor prognosis and review of previous clinical and neurophysiological cases published in the literature.
2 | MATERIALS AND METHODS

Two patients were referred to the Neurology Department of Hospital Clinic in Barcelona. The neurophysiological tests were performed with Dantec KeyPoint Net G4 electromyograph (Natus Medical Inc., Pleasanton, CA, USA) following conventional methods for routine electrodiagnostic testing. The study was approved by the Ethical Committee of the Hospital Clinic of Barcelona, and all patients gave their written informed consent which included image permission for publication.

2.1 | Case report 1

A 58-year-old man with high-grade B lymphoma received treatment with cyclophosphamide and rituximab, and triple intrathecal therapy (MTX, Ara-C, and dexamethasone) as CNS prophylaxis. He received three doses of MTX-it, with a total dose of 36 mg in three non-consecutive days. Ten days after the last lumbar puncture, he complained with lower limb weakness, which evolved into paraplegia and urinary retention. Neurological examination revealed absence of deep tendon reflexes in lower limbs and a sensory level at T1. Cerebrospinal fluid (CSF) parameters were within normal limits. Nerve conduction studies (NCS) and electromyography (EMG) performed 1 week after neurological onset showed the absence of the F wave in both lower limbs with a minimal amplitude decrease and normal latency in CMAP responses suggesting a lumbosacral polyradiculoneuropathy. No abnormalities were found in upper limbs (see Table 1 and Figure 1A,B). Lumbosacral magnetic resonance imaging

| Patient 1 | Patient 2 |
|-----------|-----------|
| Onset | After 1 wk | Onset | After 3 wk |
| Median nerve | | | |
| Motor distal latency (≤3.9 ms) | 3.2 | 3.1 | 2.9 | 2.8 |
| CMAP amplitude (≥6.0 mV) | 7.4 | 7.4 | 15 | 13 |
| Motor CV (≥50.0 m/s) | 60 | 61 | 60 | 61 |
| SNAP amplitude (≥21 µV) | 23 | 22 | ND | 26 |
| F wave latency (≤31 ms) | 29 | 29 | 24 | 23 |
| Peroneal nerve | | | |
| Motor distal latency (≤5.0 ms) | 4 | 0 | 0 | 0 |
| CMAP amplitude (≥2.0 mV) | 1.1 | 0 | 0 | 0 |
| Motor CV (≥42.0 m/s) | 45 | - | - | - |
| SNAP Amplitude (≥4.0 µV) | 6 | 6 | 8 | 2 |
| F wave latency (≤57.0 ms) | NONE | NONE | NONE | NONE |
| Tibial Posterior nerve | | | |
| Motor distal latency (≤6.0 ms) | 5.5 | 5.2 | 5.1 | 0 |
| CMAP amplitude (≥3.0 mV) | 2 | 0.3 | 1 | 0 |
| Motor CV (≥38.0 m/s) | 40 | 41 | 52 | - |
| F wave latency (≤57.0 ms) | NONE | NONE | NONE | NONE |
| Sural nerve | | | |
| Sensory distal latency (≤3.0 ms) | 2.6 | ND | 2.5 | 2.6 |
| SNAP amplitude (≥7.0 µV) | 8 | ND | 25 | 20 |
| Sensory CV (≥38.0 m/s) | 53 | ND | 62 | 52 |
| Tibialis Anterior | | | |
| Fibrillation potentials | + | +++ | ++ | +++ |
| MUP recruitment | R | R | R | R |
| Quadriceps | | | |
| Fibrillation potentials | + | +++ | ++ | +++ |
| MUP recruitment | R | R | R | R |

1 wk, one week; CMAP, compound muscle action potential; CV, conduction velocity; MUP, motor unit potential; ND, not done; NONE, no response; R, reduced; SNAP, sensory nerve action potential; Fibrillation qualitative measurement: + minimum; ++ mild; +++ moderate; ++++ severe.
(MRI) with gadolinium revealed no abnormalities. MTX-it treatment was stopped and the patient was empirically treated with intravenous methylprednisolone without improvement. One week later NCS and EMG studies showed a dramatic decrease of motor amplitudes with relatively normal latencies in peroneal and tibial posterior nerves of both sides (<1 mV) and moderate denervation in proximal and distal muscles of lower limbs (see Table 1). Thoracic spinal cord MRI revealed no abnormalities 2 months from onset. No improvement was observed after 6 months of physiotherapy and he remained with flaccid paraplegia and sensory level.

2.2 Case report 2

A 26-year-old woman previously diagnosed with acute lymphocytic leukemia in 2017 was treated with dexamethasone, vincristine, MTX, and PEG-asparaginase as consolidation therapy and MTX-it plus dexamethasone for CNS prophylaxis. She received five doses of MTX-it (total dose of 60 mg) over 5 months. Eight days after the last MTX-it injection, she developed urinary retention followed by lower limbs weakness which progressed to severe flaccid paraplegia and areflexia. CSF study revealed high protein concentration (96.4 mg/dL), with normal cell count. NCS and EMG studies at onset (10 days) and follow-up (22 and 90 days) suggested a motor lumbosacral polyradiculoneuropathy (see Table 1). Lumbosacral MRI demonstrated gadolinium enhancement of the anterior roots of the cauda equina at onset (see Figure 1C) and atrophy of dorsal columns and conus medullaris at follow-up (90 days). MTX-it was stopped but the patient showed no clinical improvement. After 6 months of physiotherapy, she persisted with flaccid paraplegia and EMG showed severe denervation of lower limb muscles.

3 DISCUSSION

To compare our findings with those of previously reported cases, we performed a comprehensive PubMed search using

---

**FIGURE 1** Case 1: Nerve conduction study at the initial phase (A) showed a relatively preserved compound motor action potential (CMAP) together with absent proximal F wave for the same nerve (proximal motor conduction block). The same study was repeated 1 wk after (B) and it showed severely decreased amplitudes without latencies delay at lower limbs. Case 2: Lumbosacral magnetic resonance imaging (MRI) at T1-weighted with gadolinium in sagittal sequences showed an enhancement of spinal cord roots at L2 level (C, arrow)
### TABLE 2  Review of clinical and other characteristics of reported cases with acute motor neuropathy related to MTX-it treatment

| Case            | Sex | Age (y) | Etiology       | Drug intrathecal | Doses (mg) | Symptoms                                                                 | CSF proteins | MRI                      | NCS                      | F wave          | Recovery, treatment                                      |
|-----------------|-----|---------|----------------|------------------|-------------|----------------------------------------------------------------------------|--------------|--------------------------|--------------------------|-----------------|----------------------------------------------------------|
| Gagliano⁴       | M   | 29      | Leukemia       | MTX              | 192         | Motor (LL) Sensory level T11, Urinary retention                            | -            | -                        | -                        | -               | Good, DXT, Fol                                          |
| Norman³         | M   | 3       | ALL            | MTX              | -           | Motor (UL + LL) Paresthesias                                               | Normal       | -                        | Axonal motor neuropathy | -               | Improved, MPS                                          |
| Koh et al⁵      | M   | 5       | ALL            | MTX              | 36          | Motor (LL), Urinary retention                                              | Elevated     | Enhancement anterior roots | Axonal motor neuropathy | -               | Good, MPS                                               |
| Koh et al⁵      | M   | 4       | ALL            | MTX              | 132         | Motor (LL) Normal                                                          | Normal       | Enhancement anterior roots | Axonal motor neuropathy | -               | Good, MPS                                               |
| Koh et al⁵      | M   | 1       | ALL            | MTX              | 48          | Motor (LL) Elevated                                                        | Enhancement anterior roots | Peroneal axonal neuropathy | -               | Improved, MPS                                          |
| Anderson¹⁶      | F   | 3       | ALL            | MTX Ara-C        | -           | Motor (UL + LL) Elevated                                                  | Enhancement anterior roots | Axonal multilevel polyradiculopathy | Absent | Good, IgIV                                              |
| González-Pérez¹⁷| M   | 19      | ALL            | MTX Ara-C        | 24          | Motor (LL), Bladder dysfunction                                            | Elevated     | Normal                   | Axonal motor neuropathy | -               | Death, IgIV                                             |
| Pascual¹⁸       | M   | 30      | ALL            | MTX              | 12          | Motor (LL), Hypopallesthesia, Urinary retention                            | Elevated     | Normal                   | Lumbosacral polyradiculopathy | Absent | No change, IgIV                                         |
| Santos-García¹⁹ | M   | 45      | ALL            | MTX Ara-C        | 36          | Motor (LL) Normal                                                          | Normal       | Enhancement anterior roots | Lumbosacral polyradiculopathy | -               | Good, MPS                                               |
| Lee²⁰           | F   | 25      | ALL            | MTX Ara-C        | 12          | Motor (LL), Sensory loss, Urinary retention                               | -            | Enhancement anterior roots | Motor neuropathy         | -               | No change, MPS                                          |
| Park et al¹¹    | M   | 58      | Lymphoma       | MTX Ara-C        | 15          | Motor (LL), Sensory level L2, Urinary retention                            | Normal       | Normal                   | Lumbosacral polyradiculopathy | Absent | No change, -                                             |
| Montejo (this article) | M   | 58      | Lymphoma       | MTX Ara-C        | 36          | Motor (LL), Sensory level L1 level, Urinary retention                     | Normal       | Normal                   | Lumbosacral polyradiculopathy | Absent | No change, -                                             |
| Montejo (this article) | F   | 26      | ALL            | MTX              | 60          | Motor (LL), Urinary retention                                              | Elevated     | Enhancement anterior roots | Lumbosacral polyradiculopathy | Absent | No change, -                                             |

ALL, acute lymphoblastic leukemia; Ara-C, Citarabine; B-NHL, B Non Hodgkin Lymphoma; CSF, cerebrospinal fluid; DXT, dexamethasone; F, female; Fo, folinic acid; IgIV, immunoglobulins intravenous; LL, lower limbs; M, male; MPS, methylprednisolone intravenous; MTX, Methotexate; NCS, nerve conduction studies; UL, upper limbs; -, unknown or no treatment.
the terms “neurotoxicity and methotrexate” and identified 11 cases. Relevant information including clinical and neurophysiological findings is summarized in Table 2. We did not include a series of 11 cases treated with MXT-it reported by Bleyer et al9 and a series of 11 cases reported by Geiser et al10 because of lack of clinical and neurophysiological information.

Neurotoxicity related to MTX-it may affect central and peripheral nervous system. Our cases highlighted that a more selective motor nerve damage was possible in contrast to immune-mediated mechanism observed in monoclonal antibody-agents such as ipilimumab or pembrolizumab,21,22 which produce a generalized pattern of acute motor neuropathy. The neurotoxic mechanism due to intrathecal administration of MTX seems to interfere in folates metabolism at spinal cord (dorsal columns and motor neurons). It may produce myelopathy7 with or without the involvement of proximal motor roots at the lumbar sacral level preferentially within days to weeks and generally has poor prognosis. Our cases emphasize that the absence of motor F wave response, which basically depends on the conduction of the proximal motor roots is an early neurophysiological sign of neurotoxicity damage and appears even earlier than the reduction of CMAP amplitude in distal motor nerves. This is noteworthy since this effect may not be dose dependent (see Table 2) but it takes some time to appear. In fact, Grzelec et al23 conducted a prospective study where he recorded F wave in two time points (before MTX-it exposure and 24 hours after) and did not observe significant changes. However, it has been described as very early sign in Guillain-Barré syndrome between 4 and 10 days after clinical onset.24

Neurophysiological studies provide relevant information to characterize the pattern of nerve damage. As an example, demyelinating peripheral neuropathy observed in Guillain-Barré syndrome or paraneoplastic-related lymphoproliferative disorders25-27 is frequently diffuse. Otherwise, mono or multifocal vasculitic pattern seen in neuroinflammation provokes a focal and direct nerve infiltration.28

In cases such as acute or subacute paraplegia related to lumbar polyradiculoneuropathy, finding the underlying mechanism (neurotoxic or immune-mediated) is challenging as it is observed in 415-18 out of 11 cases reported in Table 2. First, high protein concentration in the CSF may be present in both scenarios, and it was seen in six cases treated with MTX-it. In all cases, CSF-flow cytometry and quantitative polymerase chain reaction (PCR) of virus have to be considered to rule out infective or infiltrative aetiologies. Second, MRI gadolinium enhancement of lumbar nerve roots may not be useful to differentiate both mechanisms since it has also been reported in patients treated with MTX-it, including one of our patients.5,16,19,20 In addition, spinal cord MRI T2 hyperintensities have been described in large series of patients treated with MTX-it.7 Cachia et al7 reported seven patients with clinical features of paraplegia and sensory deficits (saddle anesthesia and/or sensory level) and 71% showed T2 hyperintensities at more than one spinal level. Third, NCS findings such as chronodispersion, prolonged latency or absent of F wave have been considered specific for demyelination29 as occur in polyneuropathies like Guillain-Barré syndrome or chronic inflammatory demyelinating neuropathy (CIDP).24,29 Regardless of the etiology, the F wave latency provides evidence of conduction block at anterior rami of root level (in this case, L5/S1 at lower limbs) and can also reflect segmental motoneuron pool excitability.30 Prolonged F wave latency and increased amplitude with dispersion have been described in patients with upper motor neuron syndromes.30 In cases of traumatic spinal block, Leis et al31 reported low persistence or absent F wave at acute phase after injury and increased F wave persistence in chronic stages. Thus, rostral spinal cord injury might produce postsynaptic changes (hyperpolarization) at caudal spinal motoneurons pool in early stages (several weeks). At follow-up, NCS-EMG revealed a progressive decrease of CMAP amplitude with denervation compatible with severe axonal degeneration. No other signs of demyelination were observed despite the absence of F wave. Therefore, the NCS-EMG may be indistinct of polyneuropathy in a chronic stage. Overall, these findings emphasize the need to perform periodic NCS-EMG from onset of clinical picture to help in the differential diagnosis process.

No standard recommendation exists for treating chemotherapy-related neurotoxicity as underlying mechanisms are unknown and there is a lack of evidence based on clinical trials. Evidence based on few clinical cases treated with methylprednisolone (MPS) with folic acid and B12 vitamin supplementation (four out of six patients) showed clinical improvement. Despite good prognosis has been reported in 6 out of 10 patients treated with MTX-it, our experience is far from good. This discrepancy may be related to different demographic features since we included only adult patients in contrast to previously reported cases that included also children (40%).

In conclusion, electrodiagnosis should be considered a valuable tool for screening of peripheral neurotoxicity by including proximal and distal motor conduction studies as necessary to detect early signs (absence of F waves) of lumbosacral motor roots damage due to MTX-it. In addition, multicentre drug vigilance programs in patients treated with neurotoxic drugs as MTX-it should be encouraged to better characterize risk factors.

ACKNOWLEDGMENTS

This study was supported in part by a grant from Instituto de Salud Carlos III, Spain (FI16/00894) and Fondo Europeo de Desarrollo Regional (FEDER).
CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTION

C. Montejo and J. Casanova-Mollá: should be considered joint first author.

ORCID

Jordi Casanova-Mollá https://orcid.org/0000-0003-0565-8015

REFERENCES

1. Adde M, Shad A, Venzon D, et al. Additional chemotherapy agent improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol. 1998;25:33-39.
2. Sancho JM, Ribera JM. Working group on diagnosis, prevention and treatment of CNS infiltration in patients with DLBCL. Central nervous system relapse in diffuse large B cell lymphoma: risk Factors. Med Clin (Barc). 2016;146:74-80.
3. Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975;45:189-195.
4. Wolff L, Zighelboim J, Gale RP. Paraplegia following intrathecal methotrexate. Pediatr Neurol. 1999;21:576-578.
5. Park S, Kang JJ, Bang H, et al. A case of cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma. Ann Rehabil Med. 2013;37:420-425.
6. Cachia D, Kamiya-Matsuoka C, Pinnix CC, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurol. 2015;122:391-398.
7. Gilbert MR, Harding BL, Grossman SA. Methotrexate neurotoxicity: in vitro studies using cerebellar explants from rats. Cancer Res. 1989;49:2502-2505.
8. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973;289:770-773.
9. Forster VJ, Mcdonnell A, Theobald R, McKay JA. Effect of methotrexate/vitB12 on DNA methylation as a potential factor in leukemia treatment-related neurotoxicity. Epigenomics. 2017;9:1205-1218.
10. Fisher MA. The contemporary role of F-wave studies. Muscle Nerve. 1998;21:1098-1101.
11. Fisher MA. F-waves: physiology and clinical uses. Scientific World Journal. 2007;7:144-160.
12. Ackermann R, Semmler A, Maurer GD, et al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurol. 2010;216:425-427.
13. Fisher MA. The contemporary role of F-wave studies. Muscle Nerve. 1998;21:1098-1101.
14. Gagliano RG, Costanzi JJ. Paraplegia following intrathecal methotrexate. Cancer. 1976;37:1663-1668.
15. Norman M, Elinder G, Finkel Y. Vincristine neuropathy and a Guillain-Barré syndrome: a case with acute lymphatic leukemia and quadriparesis. Eur J Haematol. 1987;39:75-76.
16. Anderson SC, Baquis GD, Jackson A, et al. Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. Muscle Nerve. 2002;25:106-110.
17. González-Pérez P, Serrano-Pozo A, Franco-Macias E, et al. Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma. Eur J Neurol. 2007;14(7):826-828.
18. Pascual AM, Coret F, Casanova B, et al. Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci. 2008;267:158-161.
19. Santos-García D, Pardo J, Vázquez F, et al. Pure motor lumbosacral radiculopathy after intrathecal chemotherapy. Eur J Neurol. 2008;15(8):e86-e87.
20. Lee HY, Im S, Kang MH, et al. Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia. Yonsei Med J. 2008;49:151-154.
21. Manousakis G, Koch J, Sommerville B, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013;48:440-444.
22. Sepúlveda M, Martínez-Hernandez E, Gaba L, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve. 2017;56:E162-E167.
23. Gezellec H, Fryze C, Nowacki P, Zdziarska B. F wave studies after intrathecal methotrexate administration. Acta Neurol Scand. 1996;94:276-278.
24. Alberti MA, Alentorn A, Martínez-Yelamos S, et al. Very early electdiagnostic findings in Guillain-Barré syndrome. J Periphe Nerv Syst. 2011;16:136-142.
25. Sabatelli M, Laurenti L, Luigetti M. Peripheral nervous system involvement in lymphoproliferative disorders. Mediterr J Hematol Infect Dis. 2018;10:e2018057.
26. Kelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve. 2005;31:301-313.
27. Wada M, Kurita K, Tajima K, Kawanami T, Kato T. A case of inflammatory demyelinating polyradiculoneuropathy associated with T-cell lymphoma. Acta Neurol Scand. 2003;107:62-66.
28. Tomita M, Koike H, Kawagushira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136:2563-2578.
29. Fraser JL, Olney RK. The relative diagnostic sensitivity of different F-wave parameters in various polyneuropathies. Muscle Nerve. 1992;15:912-918.
30. Fisher MA. The relative diagnostic sensitivity of different F-wave parameters in various polyneuropathies. Muscle Nerve. 1992;15:912-918.
31. Leis AA, Kronenberg MF, Stetkarova I, Paske WC, Stokie DS. Spinal motoneuron excitability after acute spinal cord injury in humans. Neurology. 1996;47:231-237.

How to cite this article: Montejo C, Navarro-Otano J, Mayá-Casalprim G, Campolo M, Casanova-Mollá J. Acute lumbar polyradiculoneuropathy as early sign of methotrexate intrathecal neurotoxicity: Case report and literature review. Clin Case Rep. 2019;7:638–643. https://doi.org/10.1002/ccr3.2026